DE2602175C3 - - Google Patents

Info

Publication number
DE2602175C3
DE2602175C3 DE2602175A DE2602175A DE2602175C3 DE 2602175 C3 DE2602175 C3 DE 2602175C3 DE 2602175 A DE2602175 A DE 2602175A DE 2602175 A DE2602175 A DE 2602175A DE 2602175 C3 DE2602175 C3 DE 2602175C3
Authority
DE
Germany
Prior art keywords
fluorouracil
acid
uracil
fluoro
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2602175A
Other languages
German (de)
English (en)
Other versions
DE2602175A1 (de
DE2602175B2 (de
Inventor
Torao Ishida
Daikichi Nishimura
Tadaaki Ooka
Toshiaki Sugawara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Kasei Corp
Original Assignee
Asahi Kasei Kogyo KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP50009469A external-priority patent/JPS5186479A/ja
Priority claimed from JP50009470A external-priority patent/JPS6024102B2/ja
Application filed by Asahi Kasei Kogyo KK filed Critical Asahi Kasei Kogyo KK
Publication of DE2602175A1 publication Critical patent/DE2602175A1/de
Publication of DE2602175B2 publication Critical patent/DE2602175B2/de
Application granted granted Critical
Publication of DE2602175C3 publication Critical patent/DE2602175C3/de
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE2602175A 1975-01-22 1976-01-21 1 -Alkanoyl-5-fluor-uracilderivate und ihre Verwendung Granted DE2602175B2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP50009469A JPS5186479A (en) 1975-01-22 1975-01-22 55 furuororashirujudotainoseizohoho
JP50009470A JPS6024102B2 (ja) 1975-01-22 1975-01-22 ５−フルオロウラシル誘導体の製法

Publications (3)

Publication Number Publication Date
DE2602175A1 DE2602175A1 (de) 1976-07-29
DE2602175B2 DE2602175B2 (de) 1978-05-03
DE2602175C3 true DE2602175C3 (enExample) 1979-01-11

Family

ID=26344210

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2602175A Granted DE2602175B2 (de) 1975-01-22 1976-01-21 1 -Alkanoyl-5-fluor-uracilderivate und ihre Verwendung

Country Status (3)

Country Link
US (1) US4088646A (enExample)
DE (1) DE2602175B2 (enExample)
FR (1) FR2298332A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7199151B2 (en) 1996-05-22 2007-04-03 Luitpold Pharmaceuticals, Inc. DHA-pharmaceutical agent conjugates of taxanes
US7816398B2 (en) 2001-03-23 2010-10-19 Luitpold Pharmaceuticals, Inc. Fatty alcohol drug conjugates
US8314077B2 (en) 1996-05-22 2012-11-20 Luitpold Pharmaceuticals, Inc. Fatty acid-pharmaceutical agent conjugates
US8552054B2 (en) 2001-03-23 2013-10-08 Luitpold Pharmaceuticals, Inc. Fatty amine drug conjugates

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR68935B (enExample) * 1976-03-31 1982-03-29 Takeda Chemical Industries Ltd
JPS5446791A (en) * 1977-09-22 1979-04-12 Takeda Chem Ind Ltd Fluorouracil derivative
US4196202A (en) * 1977-12-20 1980-04-01 Taiji Okada Carcinostatic composition containing 3-N-o-toluyl-5-fluorouracil producing the same
US4349552A (en) * 1978-10-30 1982-09-14 Fujisawa Pharmaceutical Company, Ltd. 5-Fluorouracil derivatives, and their pharmaceutical compositions
US6107499A (en) * 1988-02-26 2000-08-22 Neuromedica, Inc. Dopamine analog amide
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
JP3977162B2 (ja) * 2002-06-21 2007-09-19 株式会社バンダイナムコゲームス キャラクタ情報管理装置、プログラム及び情報記憶媒体
WO2017123823A1 (en) * 2016-01-12 2017-07-20 Bioelectron Technology Corporation Alkyl-, acyl-, urea-, and aza-uracil sulfide:quinone oxidoreductase inhibitors
RU2648998C1 (ru) * 2017-03-29 2018-03-29 Александр Александрович Озеров Способ получения монозамещенных производных урацила
RU2643520C1 (ru) * 2017-04-11 2018-02-02 Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ФГБОУ ВО ВолгГМУ МЗ РФ 1,3-Бис(4-метоксибензоил)пиримидин-2,4(1Н,3Н)-дион, обладающий разрывающей поперечные сшивки гликированных белков активностью

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2949451A (en) * 1959-04-21 1960-08-16 Hoffmann La Roche Preparation of thymidine and deoxyfluorouridine, and intermediates therefor
JPS5324951B2 (enExample) * 1973-11-28 1978-07-24

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7199151B2 (en) 1996-05-22 2007-04-03 Luitpold Pharmaceuticals, Inc. DHA-pharmaceutical agent conjugates of taxanes
US8314077B2 (en) 1996-05-22 2012-11-20 Luitpold Pharmaceuticals, Inc. Fatty acid-pharmaceutical agent conjugates
US7816398B2 (en) 2001-03-23 2010-10-19 Luitpold Pharmaceuticals, Inc. Fatty alcohol drug conjugates
US8552054B2 (en) 2001-03-23 2013-10-08 Luitpold Pharmaceuticals, Inc. Fatty amine drug conjugates

Also Published As

Publication number Publication date
US4088646A (en) 1978-05-09
FR2298332B1 (enExample) 1978-12-08
DE2602175A1 (de) 1976-07-29
FR2298332A1 (fr) 1976-08-20
DE2602175B2 (de) 1978-05-03

Similar Documents

Publication Publication Date Title
DE2602175C3 (enExample)
DE3010544C2 (de) 1H-Pyrrolo[2,1-c][1,4]benzodiazepin-2-acrylsäureamid-Verbindungen und ihre Verwendung bei der Bekämpfung maligner Neoplasien
DE1795823B2 (de) Desacetylvincaleukoblastin und seine Salze mit Säuren
DE2527914C3 (de) Vincaminderivate, Verfahren zu ihrer Herstellung und pharmazeutische Mittel
DE2426304C2 (enExample)
DE2829580C2 (de) 2-Formylchinoxalin-1,4-dioxid-cyanoacetylhydrazon, Verfahren zu seiner Herstellung und Zusammensetzungen mit dieser Verbindung
DE2119964C3 (de) Methyl N (N5 methyl N1 nitroso carbamoyiyD glycosaminid und Ver fahren zu dessen Herstellung
DE2345801A1 (de) Pyridiniumsalze
DE1802162A1 (de) Neue N-Pyridylmethyliden-homocystein-thiolacton-Verbindung und Verfahren zu ihrer Herstellung
CH636874A5 (de) Verfahren zur herstellung von neuen 5-fluoruracilderivaten und nach dem verfahren hergestellte 5-fluoruracilderivate.
DE2843136C3 (de) 6-O-Mono- und 1,6-O-Di-acylierte 2-[3-(2-Chloräthyl)-3-nitroscureido]-2-desoxy-D-glukopyranosen sowie Gemische aus 1,3,6-O-Tri und 1,4,6-O-Tri-acylierten 2-[3-(2-Chloräthyl)-3-nitrosoureido]-2-desoxy-D-glukopyranosen
DE1595894A1 (de) Neue 1,5-Diazabicyclo[3,3,0]octan-2,6-dione
DE2633926A1 (de) Hydantoinverbindungen und mittel, die diese enthalten
DE1204226B (de) Verfahren zur Herstellung von bisquaternaeren Zinnkomplexsalzen
DE2037964C3 (de) 5-NHrofuranderlvate
DE1162353B (de) Verfahren zur Herstellung von Carbaminsaeureestern
DE2526405C2 (de) β-Piperidinoäthylraubasinat und Verfahren zu dessen Herstellung
DE2313845C3 (de) Thiocarbaminsäurederivate und diese enthaltende Arzneimittelzubereitungen
DE2626559C2 (de) cis-Dichloro-dipeptidester-platin(II)-Komplexe, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
AT336587B (de) Verfahren zur herstellung von neuen basischen estern
AT230378B (de) Verfahren zur Herstellung von neuen diquartären α,ω-Bis-[pyridyl-(4)-thio]-alkanen und -dialkyläthern
DE2931079C2 (de) 1-Di-(äthylenimido)-thiophosphoryl-2-trichlormethyl-Δ↑2↑-imidazolin, dessen Herstellung und diese Verbindung enthaltende Arzneimittel
DE2119451A1 (de) Gegen dje Mareksche Krankheit nützliche Sulfanilylphenylharnstoff-Komplexe
AT258946B (de) Verfahren zur Herstellung von neuen substituierten Hydrazinverbindungen und ihren Salzen
DE2748450B2 (de) Neue Benzoyl-N'-trichloräthyUdenhydrazine und neue fungizide Zubereitungen

Legal Events

Date Code Title Description
C3 Grant after two publication steps (3rd publication)
8339 Ceased/non-payment of the annual fee